SCHEMBL3462020

SCHEMBL3462020

CCCC(N)N(CC(C)C)CC(C)C

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.33
METAP1 P53582 1/20 0.31
PLA2G1B P04054 1/20 0.30
PLA2G2A P14555 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22612192 0.84 OPRM1 (0.50) OPRM1PLA2G1BPLA2G2A
SCHEMBL3459174 0.79 ALDH1A1 (0.30)
SCHEMBL187299 0.76 PLA2G1B (0.33) OPRM1METAP1PLA2G1BPLA2G2A
SCHEMBL3237512 0.74 FDPS (0.36) OPRM1METAP1PLA2G1BPLA2G2A
SCHEMBL15668478 0.73 HTT (0.32)
SCHEMBL3460907 0.70 OPRM1 (0.38) OPRM1METAP1
SCHEMBL3460398 0.70 PLA2G1B (0.39) OPRM1PLA2G1BPLA2G2A
SCHEMBL9716803 0.70 TSHR (0.35)
SCHEMBL3461429 0.69 MAPK1 (0.35)
SCHEMBL8806714 0.69 OPRM1 (0.35) OPRM1METAP1PLA2G1BPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107540565-B Preparation of N, N- (di) alkylaminoalkyl (meth) acrylamides or the corresponding esters and quaternary ammonium salts thereof 赢创运营有限公司 2022-10-21 CN disclosed
US-8674133-B2 Method for continuously producing alkylamino(meth)acrylamides EVONIK RÖHM GMBH (DE) 2014-03-18 US disclosed
US-20110313195-A1 METHOD FOR CONTINUOUSLY PRODUCING ALKYLAMINO(METH)ACRYLAMIDES EVONIK ROEHM GMBH (DE) 2011-12-22 US disclosed
US-7723543-B2 Method for the continuous production of alkyl amino acryl amides EVONIK ROEHM GMBH (DE) 2010-05-25 US disclosed
US-7586004-B2 Method for continuously producing alkylamino(meth)acrylamides ROEHM GMBH & CO. KG (DE) 2009-09-08 US disclosed
US-20090149674-A1 METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL AMINO ACRYL AMIDES ROEHM GMBH (DE) 2009-06-11 US disclosed
US-20070149811-A1 Method for continuously producing alkylamino(meth)acrylamides ROEHM GMBH & CO. KG (DE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313195-A1 METHOD FOR CONTINUOUSLY PRODUCING ALKYLAMINO(METH)ACRYLAMIDES ACR, TET2, PAM OPRM1 2173/4885METAP1 443/4885PLA2G1B 2634/4885
US-20090149674-A1 METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL AMINO ACRYL AMIDES ACR, NAAA, AANAT OPRM1 4198/4885METAP1 1626/4885PLA2G1B 1194/4885
US-20070149811-A1 Method for continuously producing alkylamino(meth)acrylamides ACR, MMAB, TET2 OPRM1 2128/4885METAP1 522/4885PLA2G1B 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.